66 results on '"Black, Donald M."'
Search Results
2. Role of Adenylate Cyclase 9 in the Pharmacogenomic Response to Dalcetrapib
3. Study design of Dal-GenE, a pharmacogenetic trial targeting reduction of cardiovascular events with dalcetrapib
4. Dalcetrapib Reduces Risk of New-Onset Diabetes in Patients With Coronary Heart Disease
5. Association of high-density lipoprotein particle concentration with cardiovascular risk following acute coronary syndrome: A case-cohort analysis of the dal-Outcomes trial
6. Clinical Pharmacokinetics and Pharmacodynamics of Dalcetrapib
7. Cardiovascular biomarkers and surrogate end points: key initiatives and clinical trial challenges
8. New considerations in the design of clinical trials for anti-atherosclerotic drugs
9. RNAi knockdown of the focal adhesion protein TES reveals its role in actin stress fibre organisation
10. Characterisation of chicken TES and its role in cell spreading and motility
11. Therapeutic targets in cardiovascular disease: a case for high-density lipoprotein cholesterol
12. Clinical trials report
13. The development of combination drugs for atherosclerosis
14. A discussion of modalities for assessing regression and progression in vascular disease
15. Introduction
16. Lipoprotein changes with statins
17. A general assessment of the safety of HMG CoA reductase inhibitors (statins)
18. Gut-acting drugs for lowering cholesterol
19. Clinical trials report
20. Absence of ST7 mutations in tumor-derived cell lines and tumors
21. Apolipoprotein E genotype affects plasma lipid response to atorvastatin in a gender specific manner
22. Effect of niacin and atorvastatin on lipoprotein subclasses in patients with atherogenic dyslipidemia
23. Statins in children: What do we know and what do we need to do?
24. Aggressive lipid-lowering initiation abates new cardiac events (ALLIANCE)—rationale and design of atorvastatin versus usual care in hypercholesterolemic patients with coronary artery disease
25. Inhibition of cholesterol synthesis by atorvastatin in homozygous familial hypercholesterolaemia
26. Safety profile of atorvastatin-treated patients with low LDL-cholesterol levels
27. Effect of atorvastatin on hemorheologic-hemostatic parameters and serum fibrinogen levels in hyperlipidemic patients
28. The BRCA2 transactivation domain does not interact with JNK
29. Analysis of the CAVEOLIN-1 gene at human chromosome 7q31.1 in primary tumours and tumour-derived cell lines
30. Treating patients with documented atherosclerosis to national cholesterol education program-recommended low-density-lipoprotein cholesterol goals with atorvastatin, fluvastatin, lovastatin and simvastatin
31. A Multicenter, Placebo-Controlled, Dose-Ranging Study of Atorvastatin
32. Prostate cancer: New therapies in the pipeline?
33. Statins and fibrinogen
34. Efficacy and Safety in Phase II Trials
35. An Overview of the Clinical Safety Profile of Atorvastatin (Lipitor), a New HMG-CoA Reductase Inhibitor
36. Cloning and characterization of human and mouse telomerase RNA gene promoter sequences
37. A Randomized Trial of the Effects of Atorvastatin and Niacin in Patients with Combined Hyperlipidemia or Isolated Hypertriglyceridemia
38. The Cost of Reaching National Cholesterol Education Program (NCEP) Goals in Hypercholesterolaemic Patients
39. Gemfibrozil Treatment in Patients with Elevated Lipoprotein A
40. Atorvastatin, a New HMG-CoA Reductase Inhibitor, Does Not Affect Glucocorticoid Hormones in Patients with Hypercholesterolemia
41. Rationale, Design, and Baseline Characteristics of a Trial Comparing Aggressive Lipid Lowering With Atorvastatin Versus Revascularization Treatments (AVERT) fn1fn1This work is supported by a grant from Parke-Davis Pharmaceutical Research, a Division of Warner-Lambert Company, Ann Arbor, Michigan.
42. Efficacy and Safety of a New Hydroxymethylglutaryl-Coenzyme A Reductase Inhibitor, Atorvastatin, in Patients with Combined Hyperlipidemia: Comparison with Fenofibrate
43. Effect of a new HMG-CoA reductase inhibitor, atorvastatin, on lipids, apolipoproteins and lipoprotein particles in patients with elevated serum cholesterol and triglyceride levels
44. Effectiveness of Atorvastatin for Reducing Low-Density Lipoprotein Cholesterol to National Cholesterol Education Program Treatment Goals
45. Effects of regular and extended-release gemfibrozil on plasma lipoproteins and apolipoproteins in hypercholesterolemic patients with decreased HDL cholesterol levels
46. The lipid-lowering effects of atorvastatin, a new HMG-CoA reductase inhibitor: results of a randomized, double-masked study
47. Atorvastatin, a New HMG-CoA Reductase Inhibitor as Monotherapy and Combined With Colestipol
48. An Evaluation of Estrogen and Atorvastatin, A New H.MGRI, in Hypercholesterolemic Postmenopausal Women
49. Localization of the Human RNA Polymerase I Transcription Factor Gene (UBTF) to the D17S183 Locus on Chromosome 17q21 and Construction of a Long-Range Restriction Map of the Region
50. A human BRCA1 gene knockout
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.